Silence Therapeutics Appointment of Chief Medical Adviser
LONDON, September 18, 2012 /PRNewswire/ –
Silence Therapeutics plc (AIM: SLN), a leading global RNA interference (RNAi)
therapeutics company, today announces the appointment of Michael Khan to its board of
directors as Chief Medical Adviser.
Dr Michael Khan BSc, MBBS, PhD, FRCP is an Associate Professor of Medicine at the
University of Warwick and a Consultant Physician at University Hospitals. He trained in
medicine at Guy’s and King’s in London and completed specialist training at University
College London, Middlesex and Whittington Hospitals. He studied for his PhD at UCL.
He is a highly cited researcher and experienced clinician with a long track record in
metabolic medicine and cancer biology research as well as in the running of clinical
trials. He has written several books on diabetes, cholesterol problems and cancer biology
and teaches postgraduates and undergraduates in medicine and biological sciences in these
He is a previous Head of Molecular Medicine at Warwick University and has held
numerous research grants in cell and molecular biology. He and co-workers have made
important contributions to further understanding of cancer cell biology and diabetes and
are working on identifying novel tissue-based biomarkers for colorectal cancer and the
development of novel diagnostic tools. He is a fellow of the Royal College of Physicians
of London and a member of the Association of Physicians, HEART-UK and Diabetes UK and has
acted as an expert advisor to numerous National and International Organisations in both
the public and private sectors.
No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules.
Commenting on his appointment, Dr Khan said:
“I am convinced of the potential of siRNA-based therapeutics and will serve to bridge
the gap between basic and translational clinical research with the express aim of
delivering essential and urgently needed new therapies for orphan diseases and those not
well-served by currently available treatments. I believe that Silence Therapeutics core
technologies are uniquely positioned to fulfil these needs.”
Commenting on the appointment, Klaus Giese, CSO of Silence said:
“This is a highly important appointment and I am delighted that Michael has agreed to
join the Board of Silence Therapeutics. Michael’s medical, clinical and regulatory
experience will be invaluable as we look to commercialise our prospects.”
Notes for editors
About Silence Therapeutics plc (http://www.silence-therapeutics.com)
Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to
the discovery, development and delivery of targeted, systemic RNA interference (RNAi)
therapeutics for the treatment of serious diseases. Silence offers one of the most
comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on
a strong intellectual property portfolio and large clinical safety database. Silence’s
clinical siRNA product pipeline is one of the broadest in the industry. The Company
possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX(TM),
DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to
targeted diseased tissues and cells, while increasing their bioavailability and
intracellular uptake. The DACC delivery system allows functional delivery of siRNA
molecules selectively to the lung endothelium with a long duration of target mRNA and
protein knock-down. The DBTC delivery system enables functional delivery of siRNA
molecules selectively to liver cells including hepatocytes. Additionally, the Company has
a platform of novel siRNA molecules based around its AtuRNAi chemical modification
technology, which provides a number of advantages over conventional siRNA molecules.
Silence’s unique RNAi assets also include structural features for RNAi molecules and
specific design rules for increased potency and reduced off-target effects of siRNA
The Company’s lead internal drug candidate is Atu027, a liposomal formulation in
clinical development for systemic cancer indications and one of the most clinically
advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of
the Company’s technologies, AtuRNAi and AtuPLEX(TM). Silence is currently conducting an
open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with
advanced solid tumors involving single, as well as repeated, intravenous administration.
Encouraging interim safety and pharmacokinetic data were presented at the American Society
of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in
the first half of 2012.
The Company’s RNAi therapeutic platform has received key validation through multiple
partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo,
Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of
additional partnerships. Silence Therapeutics has operations in both Berlin and London.
Silence Therapeutics Ali Mortazavi +44(0)7768-694739 / Jerry Randall +44(0)7990-502000 Email: email@example.com / firstname.lastname@example.org Singer Capital Markets Shaun Dobson/Jenny Wyllie +44(0)20-32057500 email@example.com firstname.lastname@example.org M:Communications Mary-Jane Elliot / Sarah MacLeod / Claire Dickinson +44(0)20-7920-2342 email@example.com
SOURCE Silence Therapeutics Plc